Savant Capital LLC Raises Stock Position in Henry Schein, Inc. (NASDAQ:HSIC)

Savant Capital LLC grew its holdings in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 43.9% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 4,651 shares of the company’s stock after buying an additional 1,420 shares during the period. Savant Capital LLC’s holdings in Henry Schein were worth $322,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Sumitomo Mitsui DS Asset Management Company Ltd lifted its stake in Henry Schein by 2.7% during the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 12,994 shares of the company’s stock valued at $947,000 after acquiring an additional 340 shares during the period. Blue Trust Inc. lifted its position in Henry Schein by 157.0% in the third quarter. Blue Trust Inc. now owns 2,393 shares of the company’s stock worth $174,000 after buying an additional 1,462 shares during the last quarter. Tempus Wealth Planning LLC increased its stake in Henry Schein by 16.1% in the third quarter. Tempus Wealth Planning LLC now owns 5,348 shares of the company’s stock worth $390,000 after purchasing an additional 741 shares during the period. Assenagon Asset Management S.A. grew its stake in Henry Schein by 772.1% in the third quarter. Assenagon Asset Management S.A. now owns 254,580 shares of the company’s stock valued at $18,559,000 after purchasing an additional 225,388 shares during the last quarter. Finally, Cromwell Holdings LLC grew its stake in Henry Schein by 93.4% in the third quarter. Cromwell Holdings LLC now owns 352 shares of the company’s stock valued at $26,000 after purchasing an additional 170 shares during the last quarter. Institutional investors own 96.62% of the company’s stock.

Henry Schein Stock Down 2.1 %

Henry Schein stock opened at $76.00 on Tuesday. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.42 and a quick ratio of 0.82. The stock has a market capitalization of $9.48 billion, a PE ratio of 31.28, a price-to-earnings-growth ratio of 2.21 and a beta of 0.91. The business has a 50 day simple moving average of $74.03 and a 200-day simple moving average of $72.02. Henry Schein, Inc. has a 12 month low of $63.67 and a 12 month high of $82.63.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Bank of America raised Henry Schein from an “underperform” rating to a “buy” rating and raised their price target for the stock from $69.00 to $84.00 in a report on Monday, January 6th. StockNews.com raised Henry Schein from a “sell” rating to a “hold” rating in a report on Thursday, November 7th. Mizuho initiated coverage on Henry Schein in a report on Wednesday, December 4th. They set a “neutral” rating and a $75.00 target price for the company. Barrington Research lifted their target price on Henry Schein from $82.00 to $90.00 and gave the stock an “outperform” rating in a report on Thursday, January 30th. Finally, Wells Fargo & Company initiated coverage on Henry Schein in a report on Friday. They set an “equal weight” rating and a $80.00 target price for the company. Eight research analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Henry Schein has an average rating of “Moderate Buy” and an average target price of $80.09.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.